GCC Note: Slight variation exists between Saudi, UAE, Bahrain, Kuwait, Oman, Qatar labs. Always use the laboratory's own reference range. Haemoglobin thresholds for transfusion may be adjusted for sickle cell patients (target Hgb 9–10 g/dL in chronic transfusion programmes).
🧪Coagulation Studies
Test
Normal Range
Pathway
Clinical Implication
PT (Prothrombin Time)
11–13.5 seconds
Extrinsic (VII, X, V, II, I)
↑ warfarin, liver disease, Vit K deficiency
INR
0.8–1.2 (therapeutic 2–3)
Standardised PT ratio
>1.5 bleeding risk; monitor warfarin therapy
APTT (aPTT)
25–35 seconds
Intrinsic (XII, XI, IX, VIII)
↑ heparin, haemophilia A/B, DIC
Fibrinogen
2.0–4.0 g/L
Final common pathway
↓ DIC, liver failure; ↑ acute phase reaction
D-Dimer
<0.5 mg/L FEU
Fibrin degradation
↑ DVT/PE, DIC, sepsis, malignancy
Thrombin Time
14–19 seconds
Fibrinogen → fibrin conversion
↑ heparin, fibrinogen abnormality
Bleeding Time
2–9 minutes
Platelet function
↑ platelet dysfunction, VWD
DIC Alert: Disseminated intravascular coagulation = ↓Platelets + ↑PT + ↑APTT + ↓Fibrinogen + ↑D-Dimer. Report immediately to haematologist. Common in sepsis, obstetric emergencies, and haematological malignancies.
🔬Peripheral Blood Film Interpretation
Abnormal Red Cell Morphology
Sickle cells — sickle cell disease (common in GCC)
LVEF monitoring, blue discolouration warning to patient
Idarubicin
93 mg/m²
Cardiotoxicity, severe myelosuppression
Oral formulation available; vesicant protocol for IV
Vesicant Extravasation Protocol: STOP infusion immediately. Aspirate residual drug. Do NOT flush. Apply cold pack (anthracyclines) or warm pack (vinca alkaloids). Administer dexrazoxane (Savene) for anthracycline extravasation within 6 hours. Document and report. Refer to plastic surgery if tissue necrosis suspected.
Used in: AML, ALL, MDS, aplastic anaemia, haemoglobinopathies
Conditioning: Myeloablative or reduced intensity (RIC)
Engraftment typically Day +14–21 (MUD may be later)
GCC Context: High consanguinity rates in GCC populations increase availability of HLA-identical sibling donors but also increase risk of rare genetic disorders requiring transplant. King Faisal Specialist Hospital (Riyadh) and King Abdullah Medical City are major allogeneic SCT centres. UAE patients are commonly referred to Burjeel and Sheikh Khalifa Medical City.
🌙Sickle Cell Disease (Common in Saudi Arabia, Bahrain, UAE)
GCC Prevalence: Sickle cell trait/disease is among the most common genetic disorders in GCC. Carrier rates: 2–17% in Saudi Arabia (Eastern Province highest); 3–5% in Bahrain; significant numbers in UAE, Oman. National newborn screening programmes exist in Saudi Arabia and Bahrain.
Vaso-Occlusive Crisis (VOC) Management Protocol
Step
Intervention
Detail
1. Rapid Assessment
Pain score (NRS 0–10), O₂ saturation, temperature
Baseline CBC, reticulocytes, type & screen, LFTs, urinalysis
2. Analgesia (within 30 min)
Strong opioid IV/PO based on pain score
Morphine 0.1 mg/kg IV or patient's usual breakthrough dose; PCA for ongoing pain
3. Hydration
1–1.5× maintenance rate IV fluids
Normal saline or D5W 0.45% NaCl; avoid hypotonic fluids; oral hydration if tolerated
Signs: New pulmonary infiltrate + fever/chest pain/cough/hypoxia in sickle cell patient. Most common cause of SCD mortality.
Management: Simple or exchange transfusion (target HbS <30%), broad-spectrum antibiotics (cover atypicals: azithromycin), incentive spirometry, O₂, consider ICU.
Exchange Transfusion Indications
Acute stroke or TIA
Acute chest syndrome with rapid deterioration (SpO₂ <90% despite O₂)
GCC Context: Beta-thalassaemia major prevalent across GCC "thalassaemia belt." Saudi Arabia, UAE, Bahrain, Kuwait all have pre-marital screening programmes. Qatar has achieved significant reduction in new cases through prevention.
Transfusion-Dependent Thalassaemia (TDT)
Transfusion every 2–4 weeks to maintain pre-transfusion Hgb 9–10 g/dL
Use leucodepleted, ABO/Rh/Kell matched packed RBCs
Extended phenotyping (Duffy, Kidd, Kell, Lewis) to reduce alloimmunisation
Transfusion rate: 10–15 mL/kg over 3–4 hours
Monitor for febrile non-haemolytic reactions (commonest)
High consanguinity rates (25–60% of marriages in GCC countries are between first or second cousins) significantly increase the prevalence of autosomal recessive haematological disorders: sickle cell disease, thalassaemia major, Glanzmann thrombasthenia, congenital factor deficiencies, and rare enzyme deficiencies (G6PD — prevalent in GCC, especially during Ramadan/fava bean consumption).
Programme
Country
Scope
Pre-marital Screening Programme
Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman
Sickle cell, thalassaemia; couples counselled if both carriers
Newborn Screening
Saudi Arabia (national), UAE, Bahrain
Haemoglobinopathies, PKU, hypothyroidism, G6PD
Genetic Counselling Services
King Faisal Specialist, Sheikh Khalifa MC, KFSH&RC
Comprehensive hereditary haematology workup
G6PD Deficiency: Common in GCC (5–25% in some regions). Avoid: dapsone, primaquine, rasburicase, fava beans, mothballs, high-dose aspirin. Triggers haemolytic crisis. Screen before rasburicase administration.
GCC Context
🏥Key GCC Haematology & Oncology Centres
Centre
Country
Speciality Focus
Key Services
King Faisal Specialist Hospital & Research Centre (KFSH&RC)
Saudi Arabia (Riyadh, Jeddah)
Bone marrow transplant, rare haematology, paediatric oncology
Full SCT programme (allo/auto), gene therapy trials, CAR-T
All GCC: pre-marital mandatory testing for haemoglobinopathies
Common Haematological Malignancies (GCC)
NHL (Non-Hodgkin Lymphoma) — most common lymphoma
Hodgkin Lymphoma — relatively higher in young adults (EBV association)
AML — rising incidence; linked to occupational exposures
Multiple Myeloma — increasing with ageing GCC population
CLL — less common than Western populations (genetic differences)
G6PD Deficiency
Prevalence: 5–25% in GCC males (X-linked)
Screen before: rasburicase, primaquine, dapsone
Ramadan risk: some herbal medicines trigger haemolysis
Neonatal jaundice — common presentation in GCC NICUs
🌙Ramadan Considerations for Oncology Patients
Clinical Note: Fasting during Ramadan is a deeply significant religious obligation for Muslim patients. Nurses must approach this with cultural sensitivity while ensuring patient safety. Many fatally ill patients are exempt from fasting per Islamic law (shariah rukhsa), but patients may still choose to fast.
Chemotherapy Scheduling
Discuss Ramadan plans at start of each treatment cycle
Pre-hydration for cisplatin — may be scheduled at Iftar/Suhoor times
Oral chemotherapy: Take at Iftar (breaks fast) or Suhoor if once-daily
Anti-emetics: Schedule around non-fasting hours
Avoid new myelosuppressive regimens without hydration support during fasting hours
Consider delaying non-urgent chemotherapy cycles if patient insists on fasting
Medication & Monitoring Considerations
Oral medications: Religious scholars permit medications that treat illness (not nourishment) — discuss with patient's religious advisor if needed
Eye drops, nasal sprays, injections (SC/IM): generally permissible during fasting
IV hydration: breaks fast — discuss with patient
Monitor for dehydration, electrolyte imbalance, hypoglycaemia (especially steroid-containing regimens)
Blood draws: permitted during fasting
Involve hospital chaplain/imam for spiritual support
Neutropenic Patients During Ramadan
Neutropenic patients (ANC <1.0) — strongly advise against fasting
Provide written documentation for patient explaining medical exemption
Ensure antibiotic prophylaxis schedule maintained regardless of fasting
Transfusion During Ramadan
Blood transfusion: generally considered to break the fast (majority ruling)
Schedule elective transfusions for night-time (Iftar–Suhoor window) if possible
Emergency transfusions: proceed without delay regardless of fasting status
Discuss patient preferences in advance; document shared decision-making
💊Drug Procurement & Formulary Notes
Issue
GCC Context
Nursing Action
Drug availability variation
Formularies differ between Saudi (SFDA), UAE (DOH/DHA), Kuwait (MOH), etc. Some agents (e.g., posaconazole IV, carfilzomib, venetoclax) may have limited availability or require special import
Verify formulary availability before patient education; know alternative protocols
Generic substitution
Active ingredient equivalence — verify bioequivalence for narrow therapeutic index drugs (MTX, cyclosporine)
Do not substitute without pharmacist/physician approval for narrow TI drugs
Verify cold chain documentation at receipt; do not administer if cold chain breach suspected
Biosimilars
Increasingly used in GCC for G-CSF (filgrastim biosimilars), rituximab, trastuzumab
Not interchangeable without prescriber authorisation in most GCC facilities; document brand name used
Opioid regulations
Strict controlled drug regulations across all GCC countries; import restrictions; documentation requirements stringent
Detailed controlled drug register entries; dual nurse sign-off for all opioid administration
Herbal medicines
Black seed (Nigella sativa), camel milk, traditional remedies widely used by GCC patients
Screen all patients for herbal/traditional medicine use; interactions with warfarin, immunosuppressants, and P450-metabolised drugs
Practice Questions (MCQ)
Q1. A patient with AML receiving induction chemotherapy develops a temperature of 38.4°C. ANC is 0.28×10⁹/L. What is the maximum time target for first antibiotic dose administration?
The international standard (ASCO, ESMO, NICE) is IV antibiotic administration within 60 minutes of presentation with febrile neutropenia. Mortality increases by approximately 7% for each hour of delay. Neutropenic sepsis is a medical emergency requiring the same urgency as septic shock.
Q2. You are preparing to administer high-dose cytarabine (Ara-C) to a patient with AML. Which nursing intervention is specifically required for this regimen?
High-dose cytarabine can cause chemical conjunctivitis and corneal toxicity. Prophylactic steroid eye drops (e.g., dexamethasone 0.1% or prednisolone drops) are administered during and 24–48 hours after each high-dose cytarabine infusion to prevent this complication. Ice chips (cryotherapy) are used for melphalan, Mesna is used with cyclophosphamide/ifosfamide, and pre-hydration is for cisplatin.
Q3. A sickle cell patient presents with fever, chest pain, new pulmonary infiltrate on CXR, and SpO₂ of 88%. What is the priority intervention?
This patient has Acute Chest Syndrome (ACS) — the leading cause of death in sickle cell disease. SpO₂ <90% with new infiltrate requires urgent exchange transfusion (target HbS <30%), broad-spectrum antibiotics covering atypical organisms, supplemental oxygen, and ICU-level care. Hydroxyurea is a long-term preventive therapy and has no role in acute management. Reassessment alone is inadequate — this is a life-threatening emergency.
Q4. A patient on oral deferiprone (Ferriprox) for thalassaemia iron overload reports feeling unwell. Which urgent investigation is mandatory?
Deferiprone (L1/Ferriprox) carries a risk of agranulocytosis — a life-threatening drop in neutrophils (ANC <0.5×10⁹/L). Weekly CBC is mandatory for all patients on deferiprone. Any patient on deferiprone who reports feeling unwell, has fever, or signs of infection requires urgent CBC. If agranulocytosis is confirmed, deferiprone must be stopped immediately. Audiometry is a monitoring requirement for deferoxamine, not deferiprone.
Q5. A patient develops anthracycline extravasation from a peripheral cannula. What is the CORRECT sequence of immediate actions?
For anthracycline extravasation: STOP infusion immediately, aspirate residual drug through existing cannula (do not remove yet), do NOT flush (avoids spreading drug), apply cold pack (cold constricts vessels and reduces tissue uptake), and administer dexrazoxane (Savene) within 6 hours — this is the only approved antidote for anthracycline extravasation. DMSO is used for some other vesicants (mitomycin C). Warm compresses are for vinca alkaloids. Hyaluronidase is for vinca alkaloid extravasation.
Q6. A post-allogeneic SCT patient on Day +25 develops severe watery diarrhoea (>2000 mL/day), rising bilirubin (150 µmol/L), and a maculopapular rash covering 60% BSA. What is the most likely diagnosis and overall GVHD grade?
This patient has multi-organ acute GVHD: skin Stage 3 (>50% BSA rash), gut Stage 3–4 (>1500 mL diarrhoea/day), liver Stage 2–3 (bilirubin 102–255 µmol/L). This maps to overall Grade III–IV, requiring high-dose methylprednisolone (2 mg/kg/day). Ruxolitinib (a JAK1/2 inhibitor) is approved for steroid-refractory acute GVHD. C. diff should be excluded but the overall picture is GVHD given timing (Day+25 in allo-SCT window).
Q7. Which statement about MASCC score is CORRECT?
MASCC score ≥21 = LOW RISK for serious complications — suitable for oral antibiotics and close outpatient follow-up (ciprofloxacin + amoxicillin-clavulanate). Score <21 = HIGH RISK requiring hospitalisation and IV broad-spectrum antibiotics. Outpatient status at onset of fever adds 3 points (not inpatient status). Age <60 adds 2 points. Maximum score is 26.
Q8. A GCC nurse preparing rituximab for a patient with DLBCL performs pre-administration checks. Which of the following is the MOST critical pre-rituximab screening test?
Rituximab causes profound B-cell depletion and is associated with potentially fatal Hepatitis B reactivation — even in patients with resolved infection (HBsAg-negative but HBcAb-positive). Pre-treatment HBsAg and HBcAb screening is mandatory before any anti-CD20 therapy. Patients with HBcAb positivity require antiviral prophylaxis (entecavir or tenofovir) before and during rituximab treatment. TPMT/NUDT15 is for 6-mercaptopurine; G6PD is for rasburicase; HIV viral load is a separate consideration.
Q9. A thalassaemia major patient is prescribed deferasirox tablets. The nurse notices the patient is also taking a proton pump inhibitor (PPI). What is the clinical significance?
Aluminium/magnesium-containing antacids (not PPIs) significantly reduce deferasirox absorption and should not be taken simultaneously. PPIs do not have a clinically significant interaction with deferasirox. However, it is critical to verify which deferasirox formulation is being used — the dispersible tablet (Exjade) has different bioavailability from the film-coated tablet (Jadenu), and they are NOT dose-equivalent. Real nephrotoxicity monitoring is required with deferasirox (monthly creatinine, proteinuria), but co-administration with PPIs alone is not contraindicated.
Q10. A Muslim patient with AML is about to receive their second cycle of induction chemotherapy during Ramadan and insists on fasting. What is the BEST nursing approach?
Cultural and religious sensitivity is fundamental to GCC nursing practice. The correct approach is shared decision-making: explain that AML induction chemotherapy requires adequate hydration (especially for tumour lysis syndrome prevention), that neutropenic patients face increased infection risk with dehydration, and that Islamic jurisprudence (fiqh) generally permits breaking the fast for seriously ill patients. Involve the hospital imam/chaplain to support the patient's spiritual needs. Document the conversation, risks discussed, and the patient's autonomous decision. Never refuse care — offer modified scheduling (e.g., hydration at Iftar/Suhoor) as a compromise where clinically safe.